4/A - CVRx, Inc. (0001235912) (Issuer)

4 - CVRx, Inc. (0001235912) (Issuer)

4 - CVRx, Inc. (0001235912) (Issuer)

4 - CVRx, Inc. (0001235912) (Issuer)

4 - CVRx, Inc. (0001235912) (Issuer)

3 - CVRx, Inc. (0001235912) (Issuer)

4 - CVRx, Inc. (0001235912) (Issuer)

4 - CVRx, Inc. (0001235912) (Issuer)

4 - CVRx, Inc. (0001235912) (Issuer)

4 - CVRx, Inc. (0001235912) (Issuer)

4 - CVRx, Inc. (0001235912) (Issuer)

4 - CVRx, Inc. (0001235912) (Issuer)

4 - CVRx, Inc. (0001235912) (Issuer)

4 - CVRx, Inc. (0001235912) (Issuer)

4 - CVRx, Inc. (0001235912) (Issuer)

4 - CVRx, Inc. (0001235912) (Issuer)

4 - CVRx, Inc. (0001235912) (Issuer)

4 - CVRx, Inc. (0001235912) (Issuer)

SCHEDULE 13G/A - CVRx, Inc. (0001235912) (Subject)

8-K - CVRx, Inc. (0001235912) (Filer)

424B5 - CVRx, Inc. (0001235912) (Filer)

8-K - CVRx, Inc. (0001235912) (Filer)

EFFECT - CVRx, Inc. (0001235912) (Filer)

DEL AM - CVRx, Inc. (0001235912) (Filer)

S-3 - CVRx, Inc. (0001235912) (Filer)

10-Q - CVRx, Inc. (0001235912) (Filer)

8-K - CVRx, Inc. (0001235912) (Filer)

10-Q - CVRx, Inc. (0001235912) (Filer)

Analyst downgraded CVRx, Inc. from Neutral to Underweight and set a new price target of $7.00

William Blair upgraded CVRx, Inc. from Mkt Perform to Outperform

Cantor Fitzgerald initiated coverage of CVRx, Inc. with a rating of Overweight and set a new price target of $14.00

Lake Street reiterated coverage of CVRx, Inc. with a rating of Buy and set a new price target of $12.00 from $18.00 previously

Craig Hallum resumed coverage of CVRx, Inc. with a rating of Buy and set a new price target of $23.00 from $30.00 previously

JP Morgan downgraded CVRx, Inc. from Overweight to Neutral and set a new price target of $13.00 from $36.00 previously

William Blair downgraded CVRx, Inc. from Outperform to Mkt Perform

Lake Street initiated coverage of CVRx, Inc. with a rating of Buy and set a new price target of $20.00

Craig Hallum initiated coverage of CVRx, Inc. with a rating of Buy and set a new price target of $15.00

William Blair initiated coverage of CVRx, Inc. with a rating of Outperform

MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2025 financial and operating results after market close on Thursday, Feb. 12, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone

MINNEAPOLIS, Jan. 22, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced initiation of the BENEFIT-HF clinical trial, a landmark randomized study supported by CMS Category B IDE coverage and designed to evaluate the impact of Barostim™ in a significantly expanded heart failure population. Barostim™ is an implantable device that delivers electrical signals to baroreceptors located on the carotid artery, increasing baroreflex signaling, rebalancing the autonomic nervous system, and improving heart failure symptoms.

Fourth quarter revenue expected to be $15.9 million to $16.1 million, representing growth of 4% to 5%Full year revenue expected to be $56.5 million to $56.7 million, representing growth of 10% to 11%Fiscal 2026 revenue expected to be between $63 million and $67 million, representing growth of 11% to 18%Category I CPT codes and the related favorable physician fee payment levels took effect on Jan. 1, 2026FDA approved the BENEFIT-HF trial design in November and the Company has since applied to CMS for coverage for the trialDebt facility amended to extend maturity date to 2031 and to increase the facility from the $50 million of term loans already drawn by an additional $50 million, of which $1

MINNEAPOLIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, confirmed today that Category I Current Procedural Terminology (CPT) codes for baroreflex activation therapy using its Barostim device replaced the Category III codes as of Jan. 1, 2026. In the U.S. healthcare system, Category I CPT codes signify established procedures, supporting adoption, coverage, and reimbursement nationwide. The new CPT codes for use with Barostim procedures are available in the reimbursement guide here, and on

MINNEAPOLIS, Dec. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, 2026. The Company's presentation will begin at 3:45 p.m. (PT). A live webcast of the event can be found at ir.cvrx.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.About CVRx, Inc.CVRx is a c

MINNEAPOLIS, Nov. 19, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, Dec. 3, 2025. The fireside chat is scheduled at 2:00 p.m. (ET) the same day via webcast. A live audio webcast of the fireside chat will be available online at the investor relations page of the Company's website at ir.cvrx.com. About CVRx, Inc. CVRx is a commercial-stage medical device c

MINNEAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the third quarter of 2025. Recent Highlights Total revenue for the third quarter 2025 was $14.7 million, an increase of 10% over the prior year quarterU.S. revenue for the third quarter of 2025 was $13.5 million, an increase of 10% over the prior year quarterActive implanting centers in the U.S. grew to 250, an increase of 20% since September 30, 2024CMS published the final ru

MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the Jefferies Global Healthcare Conference in London on Tuesday, Nov. 18, 2025. The Company is scheduled to present at 8:00 a.m. (GMT) / 4:00 a.m. (ET) the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company's website at ir.cvrx.com. About CVRx, Inc. CVRx is a commercial-stage medica

MINNEAPOLIS, Oct. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release third quarter 2025 financial and operating results after market close on Wednesday, Nov. 5, 2025. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day.A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, p

MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2025. Recent Highlights Total revenue for the second quarter 2025 was $13.6 million, an increase of 15% over the prior year quarterU.S. Heart Failure (HF) revenue for the second quarter of 2025 was $12.1 million, an increase of 15% over the prior year quarterActive implanting centers in the U.S. grew to 240, an increase of 27% since June 30, 2024CMS propo

MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced the appointment of Robert John as Chief Revenue Officer effective June 27. In this role, John will lead the Company's US sales team with the objective of maximizing the positive impact of Barostim therapy on patients suffering from heart failure and establishing Barostim as standard of care in the United States. "We are thrilled to welcome Robert to the CVRx executive team as we continue to expand the adoption of Barostim therapy," said Kevin Hykes, President and CEO of CVRx. "Robert is well-known and respected within the heart failure community and

Appointment effective February 12 following Nadim Yared's retirement Hykes currently serves as Augmedics' President and CEO, and has served on CVRx's Board of Directors since 2022 MINNEAPOLIS, Jan. 31, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today the appointment of Kevin Hykes as the Company's new President and Chief Executive Officer, effective February 12. Hykes will continue to serve on the Company's Board of Directors. Yared will retire from the Company and resign his Board seat concurrent with Hykes' appointment and has agreed to consult with the Company to ensure a seamless transition. Hykes is an accomplishe

MINNEAPOLIS, Dec. 20, 2022 (GLOBE NEWSWIRE) --  CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Kevin Hykes will join its Board of Directors effective December 21, 2022. "We are excited to welcome an executive with the depth of expertise of Kevin Hykes to our Board of Directors," said John Nehra, lead independent director of CVRx. "His commercial experience in accelerating the growth of novel interventional therapies and his executive acumen will prove an invaluable resource as we continue to build our b

MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2025 financial and operating results after market close on Thursday, Feb. 12, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone

MINNEAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the third quarter of 2025. Recent Highlights Total revenue for the third quarter 2025 was $14.7 million, an increase of 10% over the prior year quarterU.S. revenue for the third quarter of 2025 was $13.5 million, an increase of 10% over the prior year quarterActive implanting centers in the U.S. grew to 250, an increase of 20% since September 30, 2024CMS published the final ru

MINNEAPOLIS, Oct. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release third quarter 2025 financial and operating results after market close on Wednesday, Nov. 5, 2025. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day.A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, p

MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2025. Recent Highlights Total revenue for the second quarter 2025 was $13.6 million, an increase of 15% over the prior year quarterU.S. Heart Failure (HF) revenue for the second quarter of 2025 was $12.1 million, an increase of 15% over the prior year quarterActive implanting centers in the U.S. grew to 240, an increase of 27% since June 30, 2024CMS propo

MINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter 2025 financial and operating results after market close on Monday, August 4, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, plea

MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2025. Recent Highlights Total revenue for the first quarter 2025 was $12.3 million, an increase of 15% over the prior year quarterU.S. Heart Failure (HF) revenue for the first quarter of 2025 was $11.1 million, an increase of 14% over the prior year quarterActive implanting centers in the U.S. grew to 227, an increase of 19% since March 31, 2024Real-world e

MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced that it plans to release first quarter 2025 financial and operating results after market close on Thursday, May 8, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1-800-445-7795 for U.S. callers, or 1-785-424-1699 for international callers, approximately ten minutes prior to the start time

MINNEAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced certain preliminary unaudited first quarter 2025 revenue results. "While we continue to make significant progress in driving adoption of Barostim, first quarter revenue fell short of our expectations," said Kevin Hykes, President and Chief Executive Officer of CVRx. "A core element of the commercial strategy initiated last year has been to build a world-class sales organization. As part of this effort, we brought in a number of new high-quality sales representatives in the back half of 2024 and the first quarter of 2025. We are thrilled with the lev

MINNEAPOLIS, Feb. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2024. Recent Highlights Total revenue for the fourth quarter of 2024 was $15.3 million, an increase of 36% over the prior year quarterU.S. Heart Failure (HF) revenue for the fourth quarter of 2024 was $14.3 million, an increase of 41% over the prior year quarterTotal revenue for 2024 was $51.3 million, an increase of 31% over the prior yearActive implanti

MINNEAPOLIS, Jan. 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2024 financial and operating results after market close on Tuesday, February 4, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to t